

Professor Jonas Bergh

Jonas Bergh holds the Mimi Althainz' Professorship in Oncology at the Karolinska Institutet (KI), from 2000 he was Professor of Molecular and Clinical Oncology at KI. Professor Bergh's research is mainly focused on breast cancer biology (prognostication and therapy prediction), including alteration of characteristics (clonal alterations and detection of further mutations) during progression, tailored breast cancer therapy concepts- prospective clinical studies. His research has included other cancers, including his PhD thesis on lung cancer 1984. MD from Uppsala University 1979. Bergh was appointed Distinguished Professor at KI in 2010. Since 2018 he is Theme Prefect KI for the Cancer Theme, Karolinska University Hospital and Senior Consultant at the Breast Cancer Section, Karolinska University Hospital in Stockholm, Sweden.



He was in 2019 appointed Director for the Cancer Research KI (<https://ki.se/en/cancerresearchki/cancer-research-ki>); in 2016-2019 Director for the Strategic Research Program in Cancer at KI (there was a merge of Cancer Research KI and StratCan 2019). He is a board member of Karolinska Comprehensive Cancer Center since its start 2020 and Cancer Core Europe. Bergh was Professor of Breast Oncology at Manchester University in England 2009-2010. Jonas Bergh was Chair of the Swedish Breast Cancer Group (SweBCG) between 1995 and 2016. During this period he worked in different constellations with clinical trials with better use of present drugs, new drugs and individually tailored dosing of chemotherapy. He also participated in the first randomized study showing that five years of adjuvant tamoxifen treatment resulted in an overall survival gain, compared with a previous standard of cancer treatment for two years.

Bergh was member of the ESMO/ASCO committee establishing the global curriculum for Medical Oncology. Professor Bergh was one of the funding fellows for the European Academy of Cancer Sciences.

He is an external consultant for the Swedish Medical Products Agency for more than 15 years. He has recently been a member of the scientific council IARC for WHO.

Jonas Bergh has served acting Chair of the Scientific Council in Oncology/Haematology since 2016 for the European Medicines Agency (EMA), where he was appointed member in 2004. Bergh has also been external expert for FDA. He is since 2012 Co-Chairman for a global network, Early Breast Cancer Trialists' Collaborative Group, with over 600 clinical scientists. The group's publications have a globally great impact on primary breast cancer treatment. Bergh is also a member of the consensus panels establishing treatment recommendations for primary and metastatic breast cancer; also of great importance for breast cancer treatment in many countries. Bergh has published > 500 articles, reviews and varia (*h-index 83 (Jan 11, 2021), Nr citations 40 384, average citations 62,51*).

In 2019, he received the first ESMO First Breast Cancer Award. Jonas Bergh is also fellow of the Royal College of Physicians in London, UK, Visiting Professor at Oxford University since 2017, member of the Sjöberg Prize Award Committee, member of the Nobel Assembly at KI. Bergh is also working for the Nobel Committee.

Contact:

Jonas Bergh

Tel: +46 8 524 823 38

E-mail: jonas.bergh@ki.se

